Chronic Heart Failure Pipeline Drugs Insights Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight

DelveInsight's "Chronic Heart Failure Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Chronic Heart Failure pipeline landscape. It covers the Chronic Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Heart Failure pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive Chronic Heart Failure Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Chronic Heart Failure Pipeline Outlook Report [https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Heart Failure Pipeline Report

* On 08 October 2025, Yale University announced a study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy.
* On 08 October 2025, Regeneron Pharmaceuticals conducted a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction.
* On 07 October 2025, Boehringer Ingelheim organized a study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure.
* On 03 October 2025, Cardurion Pharmaceuticals Inc . announced a study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction.
* DelveInsight's Chronic Heart Failure pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Chronic Heart Failure treatment.
* The leading Chronic Heart Failure Companies such as Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics and others.
* Promising Chronic Heart Failure Pipeline Therapies such as Ertugliflozin, Metolazone, nesiritide, furosemide, Levosimendan, AZD5462, TSG-01, JTT-861 Capsules, rhNRG-1 and others.

Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Heart Failure Clinical Trials and Studies [https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Chronic Heart Failure Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Chronic Heart Failure Pipeline Report also highlights the unmet needs with respect to the Chronic Heart Failure.

Chronic Heart Failure Overview

Chronic Heart Failure (CHF) is a major public health problem in industrialized societies with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45-55, 2-5% between ages 65-75, and approximately 10% for patients aged 80 years or more. Heart Failure is a complex clinical syndrome characterized by the inability of the heart to provide the cardiac output needed by the organism at normal end-diastolic ventricular pressures. Ventricular dysfunction limits exercise tolerance and may impair the quality of life of affected individuals. Clinically, forward failure of the heart leads to low blood pressure and fatigue, while backward failure results in dyspnea and fluid retention, which may lead to pulmonary congestion, pleural effusions, peripheral edema, as well as impairment of hepatic, gastric, and renal function.

Chronic Heart Failure Emerging Drugs Profile

* Neucardin: Zensun (Shanghai) Sci & Tech

Neucardin is a. Recombinant human neuregulin-1 (Neucardin), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The advantage of Neucardin Registered is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving cardiac function and reversing pathological ventricular remodeling, and significantly reducing death rate and readmission rate while improving the quality of life. In August 2019, Zensun USA, Inc., announced that the investigation of NEUCARDIN, its Recombinant human neuregulin-1 fragment, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of Chronic Heart Failure (CHF). NEUCARDIN, the lead drug candidate from the company's cardiac therapy program, was also recently granted "priority review" for its conditional approval application in China by the National Medical Products Administration (NMPA) (formerly the CFDA).

* Omecamtiv Mecarbil: Cytokinetics

Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator, the first of a novel class of myotropes1 designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin heads to interact with actin during systole. Omecamtiv mecarbil is designed to increase the number of active actin-myosin cross bridges during each cardiac cycle and consequently augment the impaired contractility that is associated with heart failure with reduced ejection fraction (HFrEF). Preclinical research has shown that omecamtiv mecarbil increases cardiac contractility without increasing intracellular myocyte calcium concentrations or myocardial oxygen consumption.

* Rexlemestrocel-L (Revascor): Mesoblast

Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Heart Failure.

Get a detailed analysis of the latest innovations in the Chronic Heart Failure pipeline. Explore DelveInsight's expert-driven report today! @ Chronic Heart Failure Unmet Needs [https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Chronic Heart Failure pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Heart Failure with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Heart Failure Treatment.
* Chronic Heart Failure Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chronic Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Heart Failure market.

Chronic Heart Failure Companies

Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics and others.

Chronic Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Chronic Heart Failure Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Thy Chronic Heart Failure Developments @ Chronic Heart Failure Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chronic Heart Failure Pipeline Report

* Coverage- Global
* Chronic Heart Failure Companies- Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics and others.
* Chronic Heart Failure Pipeline Therapies- Ertugliflozin, Metolazone, nesiritide, furosemide, Levosimendan, AZD5462, TSG-01, JTT-861 Capsules, rhNRG-1 and others.
* Chronic Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Chronic Heart Failure drug development? Find out in DelveInsight's exclusive Pipeline Report-access it now! @ Chronic Heart Failure Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/chronic-heart-failure-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Chronic Heart Failure: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Heart Failure- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Neucardin: Zensun (Shanghai) Sci & Tech
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Chronic Heart Failure Key Companies
* Chronic Heart Failure Key Products
* Chronic Heart Failure - Unmet Needs
* Chronic Heart Failure - Market Drivers and Barriers
* Chronic Heart Failure - Future Perspectives and Conclusion
* Chronic Heart Failure Analyst Views
* Chronic Heart Failure Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-heart-failure-pipeline-drugs-insights-report-2025-emerging-therapies-clinical-developments-and-drug-insights-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-heart-failure-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.